Eli Lilly and Co (LLY) Shares Sold by Rathbone Brothers plc

Rathbone Brothers plc lowered its position in shares of Eli Lilly and Co (NYSE:LLY) by 2.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 94,826 shares of the company’s stock after selling 2,614 shares during the period. Rathbone Brothers plc’s holdings in Eli Lilly and were worth $7,976,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in LLY. Bank of Montreal Can increased its stake in shares of Eli Lilly and by 5.2% in the third quarter. Bank of Montreal Can now owns 1,156,017 shares of the company’s stock worth $92,781,000 after buying an additional 57,025 shares in the last quarter. Davis R M Inc. increased its stake in shares of Eli Lilly and by 4.4% in the third quarter. Davis R M Inc. now owns 13,417 shares of the company’s stock worth $1,077,000 after buying an additional 560 shares in the last quarter. Farmers & Merchants Investments Inc. increased its stake in shares of Eli Lilly and by 27.9% in the third quarter. Farmers & Merchants Investments Inc. now owns 38,429 shares of the company’s stock worth $3,084,000 after buying an additional 8,377 shares in the last quarter. First Quadrant L P CA increased its stake in shares of Eli Lilly and by 14,534.1% in the third quarter. First Quadrant L P CA now owns 219,511 shares of the company’s stock worth $17,618,000 after buying an additional 218,011 shares in the last quarter. Finally, RNC Capital Management LLC increased its stake in shares of Eli Lilly and by 3.1% in the third quarter. RNC Capital Management LLC now owns 423,344 shares of the company’s stock worth $33,978,000 after buying an additional 12,560 shares in the last quarter. 75.15% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Shares of Eli Lilly and Co (NYSE:LLY) traded up 0.31% during midday trading on Friday, reaching $82.19. The company’s stock had a trading volume of 1,694,567 shares. Eli Lilly and Co has a 12-month low of $64.18 and a 12-month high of $86.72. The company has a market cap of $86.37 billion, a P/E ratio of 31.86 and a beta of 0.30. The stock’s 50-day moving average price is $84.25 and its 200-day moving average price is $77.93.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, January 31st. The company reported $0.95 EPS for the quarter, missing the Zacks’ consensus estimate of $0.98 by $0.03. The company had revenue of $5.76 billion for the quarter, compared to the consensus estimate of $5.54 billion. Eli Lilly and had a return on equity of 24.74% and a net margin of 12.90%. Eli Lilly and’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.78 earnings per share. On average, analysts expect that Eli Lilly and Co will post $4.11 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Eli Lilly and Co (LLY) Shares Sold by Rathbone Brothers plc” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2017/04/21/rathbone-brothers-plc-has-7976000-stake-in-eli-lilly-and-co-lly-updated.html.

A number of analysts recently issued reports on the company. Cowen and Company raised their price target on Eli Lilly and from $85.00 to $95.00 and gave the stock an “outperform” rating in a research report on Monday. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a research report on Tuesday, April 4th. Citigroup Inc reiterated a “buy” rating and set a $100.00 target price on shares of Eli Lilly and in a research report on Thursday, April 6th. Morgan Stanley downgraded Eli Lilly and from an “overweight” rating to an “equal weight” rating and set a $82.00 target price for the company. in a research report on Monday. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $97.00 target price on shares of Eli Lilly and in a research report on Monday, April 10th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $88.70.

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction on Thursday, March 30th. The stock was sold at an average price of $84.67, for a total transaction of $17,780,700.00. Following the completion of the transaction, the insider now directly owns 124,690,804 shares in the company, valued at approximately $10,557,570,374.68. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Derica W. Rice sold 11,162 shares of the company’s stock in a transaction on Friday, February 3rd. The stock was sold at an average price of $77.14, for a total value of $861,036.68. Following the transaction, the executive vice president now owns 58,443 shares of the company’s stock, valued at $4,508,293.02. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 688,162 shares of company stock valued at $55,440,777. 0.20% of the stock is owned by company insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply